Aspire Biopharma Holdings, Inc. (ASBPW)Stock Price & Financial Statements
AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more
- Revenue $0
- EBITDA -$12M -360.4%
- Net Income -$13M -380.8%
- EPS (Diluted) -1.52 -381.5%
- Gross Margin -
- EBITDA Margin -
- Operating Margin -
- Net Margin -
- ROE -
- ROIC -
- Debt/Equity -
- Interest Coverage -3.46 +97.7%
Key Insights
Based on financial data analysisStrengths
No significant strengths identified
Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
Price & Volume
Loading chart...
Growth Metrics
Revenue CAGR
10Y-
5Y-
3Y-
TTM-
Profit (Net Income) CAGR
10Y-
5Y-
3Y-
TTM-6467.87%
EPS CAGR
10Y-
5Y-
3Y-
TTM-1740.89%
ROCE
10Y Avg-
5Y Avg-
3Y Avg-
Latest-
Peer Comparison
Diagnostics and Omics Tools| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
 VCYTVeracyte, Inc. | 2.88B | 36.27 | 44.23 | 16.01% | 12.83% | 5.07% | 4.4% | 0.03 |
ASBPWAspire Biopharma Holdings, Inc. | 178.9K | 0.02 | -0.01 | -16351.77% | ||||
 VRAXVirax Biolabs Group Limited | 1.55M | 0.21 | -0.11 | -95.95% | -78.62% | -234.24% | 0.07 | |
 CDIOCardio Diagnostics Holdings, Inc. | 141.46M | 5.26 | -0.57 | 104.45% | -415.16% | -80.38% | 0.10 | |
 AIMDAinos, Inc. | 7.24M | 1.51 | -0.97 | -83.02% | -132.32% | -148.9% | 0.77 | |
 IMDXInsight Molecular Diagnostics Inc. | 95.47M | 5.47 | -1.17 | 25.15% | -13.81% | -14.81% | ||
 SEERSeer, Inc. | 103.2M | 1.85 | -1.33 | -8.13% | -486.02% | -29.19% | 0.08 | |
 ASBPAspire Biopharma Holdings, Inc. | 62.88M | 1.32 | -5.08 | -16351.99% |
Compare ASBPW vs Peers
Analyze head-to-head performance against top industry competitors across valuation, growth, and profitability metrics.
Income Statement
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 |
| Revenue Growth % | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - |
| Gross Profit | 0 | 0 | 0 |
| Gross Margin % | - | - | - |
| Gross Profit Growth % | - | - | - |
| Operating Expenses | 976.35K | 1.34M | 3.09M |
| OpEx % of Revenue | - | - | - |
| Selling, General & Admin | 421.18K | 1.34M | 3.09M |
| SG&A % of Revenue | - | - | - |
| Research & Development | 175.32K | 72.05K | 0 |
| R&D % of Revenue | - | - | - |
| Other Operating Expenses | 379.85K | -72.05K | 0 |
| Operating Income | -976.35K | -1.34M | -3.09M |
| Operating Margin % | - | - | - |
| Operating Income Growth % | - | -37.26% | -130.47% |
| EBITDA | -596K | 4.47M | -11.65M |
| EBITDA Margin % | - | - | - |
| EBITDA Growth % | - | 850.5% | -360.36% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 |
| EBIT | -596K | 4.47M | -11.65M |
| Net Interest Income | 4.32M | 5.8M | -343K |
| Interest Income | 4.32M | 5.81M | 548.68K |
| Interest Expense | 0 | 8.97K | 891.62K |
| Other Income/Expense | 379.97K | 5.8M | -9.45M |
| Pretax Income | -596.37K | 4.46M | -12.54M |
| Pretax Margin % | - | - | - |
| Income Tax | 626 | 0 | 0 |
| Effective Tax Rate % | 100.11% | 100% | 100% |
| Net Income | -597K | 4.46M | -12.54M |
| Net Margin % | - | - | - |
| Net Income Growth % | - | 847.74% | -380.85% |
| Net Income (Continuing) | -597K | 4.46M | -12.54M |
| Discontinued Operations | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
| EPS (Diluted) | -0.07 | 0.54 | -1.52 |
| EPS Growth % | - | 845.86% | -381.48% |
| EPS (Basic) | -0.07 | 0.54 | -1.52 |
| Diluted Shares Outstanding | 8.24M | 8.24M | 8.24M |
| Basic Shares Outstanding | 8.24M | 8.24M | 8.24M |
| Dividend Payout Ratio | - | - | - |
Balance Sheet
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Total Current Assets | 22.54K | 46.17K | 147.99K |
| Cash & Short-Term Investments | 38 | 11.17K | 3.63K |
| Cash Only | 38 | 11.17K | 3.63K |
| Short-Term Investments | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 36.5K |
| Days Sales Outstanding | - | - | - |
| Inventory | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - |
| Other Current Assets | 0 | 0 | -36.5K |
| Total Non-Current Assets | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - |
| Goodwill | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 |
| Long-Term Investments | 299M | 19.9M | 6.67M |
| Other Non-Current Assets | -303.9M | -24.87M | -6.67M |
| Total Assets | 22.54K | 46.17K | 147.99K |
| Asset Turnover | - | - | - |
| Asset Growth % | - | 104.87% | 220.5% |
| Total Current Liabilities | 151.33K | 534.03K | 1.69M |
| Accounts Payable | 122.73K | 172.77K | 310.22K |
| Days Payables Outstanding | - | - | - |
| Short-Term Debt | 27.97K | 360.64K | 1.27M |
| Deferred Revenue (Current) | 0 | 0 | 0 |
| Other Current Liabilities | 626 | 626 | 111.03K |
| Current Ratio | 0.15x | 0.09x | 0.09x |
| Quick Ratio | 0.15x | 0.09x | 0.09x |
| Cash Conversion Cycle | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 |
| Long-Term Debt | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 |
| Total Liabilities | 151.33K | 534.03K | 1.69M |
| Total Debt | 27.97K | 360.64K | 1.27M |
| Net Debt | 27.93K | 349.46K | 1.26M |
| Debt / Equity | - | - | - |
| Debt / EBITDA | - | 0.08x | - |
| Net Debt / EBITDA | - | 0.08x | - |
| Interest Coverage | - | -149.47x | -3.46x |
| Total Equity | -128.79K | -487.86K | -1.54M |
| Equity Growth % | - | -278.8% | -215.68% |
| Book Value per Share | -0.02 | -0.06 | -0.19 |
| Total Shareholders' Equity | -128.79K | -487.86K | -1.54M |
| Common Stock | 221.5K | 22K | 22K |
| Retained Earnings | -1.11M | -1.47M | -2.78M |
| Treasury Stock | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 |
Cash Flow Statement
| Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|
| Cash from Operations | -142.91K | 11.14K | -265.19K |
| Operating CF Margin % | - | - | - |
| Operating CF Growth % | - | 107.79% | -2481.34% |
| Net Income | -597.12K | -359.07K | -1.31M |
| Depreciation & Amortization | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Deferred Taxes | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 |
| Working Capital Changes | 454.21K | 370.21K | 1.04M |
| Change in Receivables | 400K | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 |
| Change in Payables | 102.73K | 50.04K | 0 |
| Cash from Investing | -4.9M | 284.92M | 13.78M |
| Capital Expenditures | -4.9M | -75.9K | 0 |
| CapEx % of Revenue | - | - | - |
| Acquisitions | 0 | 0 | 0 |
| Investments | - | - | - |
| Other Investing | 0 | 284.99M | 0 |
| Cash from Financing | 4.85M | -284.76M | 257.64K |
| Debt Issued (Net) | -252.91K | 0 | 1.71M |
| Equity Issued (Net) | 1000K | -1000K | 257.64K |
| Dividends Paid | 0 | 0 | 0 |
| Share Repurchases | 0 | -284.92M | 0 |
| Other Financing | 4.11M | 0 | -1.71M |
| Net Change in Cash | -185.46K | 11.14K | -7.54K |
| Free Cash Flow | -5.04M | -653.11K | -265.19K |
| FCF Margin % | - | - | - |
| FCF Growth % | - | 87.04% | 59.4% |
| FCF per Share | -0.61 | -0.08 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.24x | 0.00x | 0.02x |
| Interest Paid | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.01K |
Key Ratios
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Interest Coverage | - | -149.47x | -3.46x |
| FCF Conversion | 0.24x | 0.00x | 0.02x |
Deep Dive Analysis
Explore detailed financial history, valuation models, and returns analysis
Valuation Overview
DCF models, peer multiples & analyst estimates
Total Return Calculator
Historical returns with dividends reinvested
Dividend History
Yield, growth, payout safety & DRIP calculator
Earnings History
EPS trends, net income & profitability analysis
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of valuation, profitability & efficiency metrics